lifestyle.smarttalksuccess.com

Author: Pentixapharm Holding AG

Pentixapharm Announces IND Submission to FDA for Phase 3 PANDA Study of First-in-Class CXCR4-Targeted Cardiovascular Diagnostic

May 11, 2026
Pentixapharm Receives FDA “Study May Proceed” Letters for Dual Theranostic INDs in CXCR4-Based Hemato-Oncology Program

February 25, 2026
Pentixapharm Announces Peer-Reviewed Phase 2 Data Back Use of PENTIXAFOR as a Superior Non-invasive PET-Diagnostic for Primary Aldosteronism

February 10, 2026
Pentixapharm Receives FDA Feedback for Phase 3 Diagnostic Study in Hypertension

January 7, 2026